Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300053 · ClinicalTrials.gov registry record · Phase 2
ACT34-CMI -- Adult Autologous CD34+ Cells
A Phase 2 study of Myocardial Ischemia, sponsored by Lisata Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 321
- Enrollment target
- 20
- Study locations
NCT00300053: Completed Phase 2 study of Myocardial Ischemia, sponsored by Lisata Therapeutics.
NCT00300053 is a Phase 2 study of Myocardial Ischemia that has completed, run by Lisata Therapeutics. The registered enrollment target is 321 participants, below the 2,127-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00300053, a Phase 2 study of Myocardial Ischemia, has completed, sponsored by Lisata Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 321 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of intramyocardial injections of CLBS14 in patients with refractory chronic myocardial ischemia.
Primary Outcome
The number of angina episodes were collected via an electronic subject diary for four weeks at Baseline and at 6 and 12 months. The four-week angina episodes (per week mean) were used as the frequency for each visit. A lower number represents fewer angina episodes. A lower number is better.
Conditions Studied
Interventions
- BIOLOGICAL CLBS14 (low-dose)
- BIOLOGICAL CLBS14 (high-dose)
- BIOLOGICAL placebo injection
Study Locations (20)
Florida
- Holy Cross Hospital - Fort Lauderdale
- University of Florida Health Science Center - Gainesville
- University of Florida Health Science Center - Jacksonville
- Central Florida Cardiology Group - Orlando
Arizona
- Arizona Heart Institute - Phoenix
- Mayo Clinic Hospital - Phoenix
California
- Scripps Memorial Hospital - La Jolla
- Stanford University Hospital and Clinics - Stanford
Illinois
- Northwestern University Medical Center, Bluhm Cardiovascluar Institute - Chicago
- Rush University Medical Center - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
- Caritas Saint Elizabeth's Medical Center - Boston
New York
- New York Presbyterian Hospital - Columbia University Medical Center - New York
- New York Presbyterian Hospital - Weill Cornell Medical College of Cornell University - New York
Alabama
- Cardiology PC - Birmingham
District of Columbia
- Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
What the finished NCT00300053 record still lists
NCT00300053 is an interventional study that assigns participants to a tested intervention. The registered 321 participants enrollment target is mid-sized for trials with a published cap, below the 2,127-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Myocardial Ischemia appearing as the primary indexed condition, and to 3 interventions - of which CLBS14 (low-dose) is the first listed.
NCT00300053 names 20 study sites across 12 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00300053 about?
NCT00300053 is a clinical study titled "ACT34-CMI -- Adult Autologous CD34+ Cells". The purpose of this study is to evaluate the efficacy and safety of intramyocardial injections of CLBS14 in patients with refractory chronic myocardial ischemia.
What is the current status of trial NCT00300053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 321 participants. The study started on 2006-04. Estimated completion is 2009-03.
What conditions does trial NCT00300053 study?
This clinical trial studies the following conditions: Myocardial Ischemia.
What interventions are being tested in trial NCT00300053?
The interventions under investigation include: CLBS14 (low-dose) (BIOLOGICAL), CLBS14 (high-dose) (BIOLOGICAL), placebo injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT00300053?
This trial is sponsored by Lisata Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00300053 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Ischemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00300053's enrollment target sits among peer trials
321 14th of 29 higher than 16 of 29 other Myocardial Ischemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myocardial Ischemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery
COMPLETED · Phase 2
-
Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
COMPLETED · Phase 2
-
Nitric Oxide Inhalation Therapy to Relieve Chest Pain in Patients With Coronary Artery Disease
COMPLETED · Phase 2
-
Ranolazine Mediated PVC Reduction in Ischemic Heart Disease
COMPLETED · Phase 2
-
Bright Light Exposure in Surgical Patients
RECRUITING · NA
-
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03715933 · 321 participants · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia